ADYNXX, INC.
DNA decoy oligonucleotides (brivoligide and AYX2) that inhibit transcription factors to treat chronic pain
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2007
- Latest Form D
- $16M, Jan 2017
- Total capital
- $22.2M
- Federal grants
- $603K
- 1 award · 2019
- Rank in peer group#161 of 502
- Private capital raised
- $21.6M
- 4 Form D · last Jan 2017
- 117 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 9 pending · first 2016
- Rank in peer group#17 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain$603K
- Private capital raisedForm D · SEC · 4th filing$16M
- Private capital raisedForm D · SEC · 3rd filing$4.8M
- Private capital raisedForm D · SEC · 2nd filing$39K
- Private capital raisedForm D · SEC · 1st filing$741K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#161 · top 32%
- Granted patents#17 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Julien MametResearcherExecutive Officer, DirectorLinked by 5 patents · $603K in grants as PI
- Dennis PodlesakDirectorNamed in SEC Form D filings
- Donald ManningExecutive OfficerNamed in SEC Form D filings
- Eckard WeberDirectorNamed in SEC Form D filings
- George BarnettDirectorNamed in SEC Form D filings
- Heath LukatchDirectorNamed in SEC Form D filings
Show all 10 people
- Michael AshleyDirectorNamed in SEC Form D filings
- Rick OrrExecutive Officer, DirectorNamed in SEC Form D filings
- Scott HarrisExecutive OfficerNamed in SEC Form D filings
- Stan AbelDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 14- PendingCompositions And Methods For Pain Amelioration Via Modification Of Gene ExpressionUSPTOApplication 16080547
- GrantedFormulations For The Delivery Of Active IngredientsUSPTOUS 10,434,178
- GrantedOligonucleotide Decoys For The Treatment Of PainUSPTOUS 10,287,583
Show all 14 patent records
- Compositions And Methods For Pain Amelioration Via Modification Of Gene ExpressionJan 16, 2020 · Application 16080547Pending
- Formulations For The Delivery Of Active IngredientsOct 8, 2019 · US 10,434,178Granted
- Oligonucleotide Decoys For The Treatment Of PainMay 14, 2019 · US 10,287,583Granted
- Gene Expression And PainAug 7, 2018 · US 10,041,069Granted
- Formulations For The Delivery Of Active IngredientsJul 11, 2017 · US 9,700,624Granted
- Gene Expression And PainMar 22, 2016 · US 9,290,762Granted
- Compositions And Methods For Pain Amelioration Via Modification Of Gene ExpressionApplication 62301272Pending
- Compositions And Methods For Pain Amelioration In A High Catastrophizing Patient PopulationApplication 62634666Pending
- Oligonucleotide Decoys For The Treatment Of PainApplication PCTUS2015045268Pending
- Oligonucleotide Decoys For The Treatment Of PainApplication 62037996Pending
- Formulations For The Delivery Of Active IngredientsApplication PCTUS2013040426Pending
- Compositions And Methods For Pain Amelioration Via Modification Of Gene ExpressionApplication PCTUS2017019989Pending
- Gene Expression And PainApplication PCTUS2008063471Pending
- Compositions And Methods For Pain Amelioration Via Modification Of Gene ExpressionApplication 62421456Pending
Related companies, and why
- PROTAGONIST THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- TATEVA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- DFI Holding Inc.Similar federal contract value in Biotech · null in contracts
- Distributed Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Sonoma BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
- SUNOMIX THERAPEUTICSSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .